BRPI0906996B1 - Composto de quinazolino-2, 4-diona, processo para preparar um composto, e, composição farmacêutica - Google Patents

Composto de quinazolino-2, 4-diona, processo para preparar um composto, e, composição farmacêutica Download PDF

Info

Publication number: BRPI0906996B1
Authority: BR; Brazil
Prior art keywords: dioxo; dihydro; quinazolin; propyl; butyl
Prior art date: 2008-01-30

Application number

BRPI0906996-8A

Other languages

English (en)

Portuguese (pt)

Inventor

Il Hwan Cho

Eun Bang Lee

Sin Cheol Kang

Won Seok Kim

Chul Kyu Lee

Original Assignee

Shin Poong Pharmaceutical Co., Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-01-30

Filing date

2009-01-08

Publication date

2021-06-22

2009-01-08 Application filed by Shin Poong Pharmaceutical Co., Ltd filed Critical Shin Poong Pharmaceutical Co., Ltd

2015-07-07 Publication of BRPI0906996A2 publication Critical patent/BRPI0906996A2/pt

2021-06-22 Publication of BRPI0906996B1 publication Critical patent/BRPI0906996B1/pt

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 140
-1 QUINAZOLINE-2, 4-DIONE COMPOUND Chemical class 0.000 title claims abstract description 47
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
238000004519 manufacturing process Methods 0.000 title claims abstract description 12
150000003839 salts Chemical class 0.000 claims abstract description 47
239000000203 mixture Substances 0.000 claims abstract description 9
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 91
239000001257 hydrogen Substances 0.000 claims description 33
229910052739 hydrogen Inorganic materials 0.000 claims description 33
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 25
239000002253 acid Substances 0.000 claims description 23
238000006243 chemical reaction Methods 0.000 claims description 21
210000002569 neuron Anatomy 0.000 claims description 20
FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 claims description 20
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 19
125000000217 alkyl group Chemical group 0.000 claims description 18
125000006308 propyl amino group Chemical group 0.000 claims description 18
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
229910052736 halogen Inorganic materials 0.000 claims description 13
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 12
150000002367 halogens Chemical group 0.000 claims description 11
239000002904 solvent Substances 0.000 claims description 11
GEKVQQRWANFZJR-UHFFFAOYSA-N 3-[3-[4-[3-(2,4-dioxo-1h-quinazolin-3-yl)propylamino]butylamino]propyl]-1h-quinazoline-2,4-dione Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCNCCCCNCCCN1C(=O)C2=CC=CC=C2NC1=O GEKVQQRWANFZJR-UHFFFAOYSA-N 0.000 claims description 10
208000006011 Stroke Diseases 0.000 claims description 10
239000004480 active ingredient Substances 0.000 claims description 10
206010008118 cerebral infarction Diseases 0.000 claims description 10
208000026106 cerebrovascular disease Diseases 0.000 claims description 10
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
208000028867 ischemia Diseases 0.000 claims description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
230000000926 neurological effect Effects 0.000 claims description 9
208000014644 Brain disease Diseases 0.000 claims description 8
201000010099 disease Diseases 0.000 claims description 8
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
DMGJYMZSBLSOAU-UHFFFAOYSA-N 3-[3-[4-(3-aminopropylamino)butylamino]propyl]-1h-quinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)N(CCCNCCCCNCCCN)C(=O)NC2=C1 DMGJYMZSBLSOAU-UHFFFAOYSA-N 0.000 claims description 7
MLAJKFBHELLQJC-UHFFFAOYSA-N 3-[4-[3-(2,4-dioxo-1h-quinazolin-3-yl)propylamino]butyl]-1h-quinazoline-2,4-dione Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCNCCCCN1C(=O)C2=CC=CC=C2NC1=O MLAJKFBHELLQJC-UHFFFAOYSA-N 0.000 claims description 7
208000024827 Alzheimer disease Diseases 0.000 claims description 7
125000006309 butyl amino group Chemical group 0.000 claims description 7
206010015037 epilepsy Diseases 0.000 claims description 7
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 claims description 7
SJZBPVOSFYUHFV-UHFFFAOYSA-N n-[3-(2,4-dioxo-1h-quinazolin-3-yl)propyl]-n-[4-[3-(2,4-dioxo-1h-quinazolin-3-yl)propylamino]butyl]acetamide Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCN(C(=O)C)CCCCNCCCN1C(=O)C2=CC=CC=C2NC1=O SJZBPVOSFYUHFV-UHFFFAOYSA-N 0.000 claims description 7
206010008111 Cerebral haemorrhage Diseases 0.000 claims description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
208000032382 Ischaemic stroke Diseases 0.000 claims description 5
208000018737 Parkinson disease Diseases 0.000 claims description 5
208000030886 Traumatic Brain injury Diseases 0.000 claims description 5
230000001154 acute effect Effects 0.000 claims description 5
230000007850 degeneration Effects 0.000 claims description 5
230000003412 degenerative effect Effects 0.000 claims description 5
125000004494 ethyl ester group Chemical group 0.000 claims description 5
DLIGBESRVOXZJX-UHFFFAOYSA-N n-[3-[4-[3-(2,4-dioxo-1h-quinazolin-3-yl)propylamino]butylamino]propyl]-4-hydroxybenzamide Chemical compound C1=CC(O)=CC=C1C(=O)NCCCNCCCCNCCCN1C(=O)C2=CC=CC=C2NC1=O DLIGBESRVOXZJX-UHFFFAOYSA-N 0.000 claims description 5
JBZGLYIWQCCGSY-UHFFFAOYSA-N 3-[2-[3-[2-(2,4-dioxo-1h-quinazolin-3-yl)ethylamino]propylamino]ethyl]-1h-quinazoline-2,4-dione Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCNCCCNCCN1C(=O)C2=CC=CC=C2NC1=O JBZGLYIWQCCGSY-UHFFFAOYSA-N 0.000 claims description 4
208000023105 Huntington disease Diseases 0.000 claims description 4
208000027747 Kennedy disease Diseases 0.000 claims description 4
208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 4
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 4
125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 4
TZKOJMOVKKJLNP-UHFFFAOYSA-N n-[3-(2,4-dioxo-1h-quinazolin-3-yl)propyl]-n-[4-[3-(2,4-dioxo-1h-quinazolin-3-yl)propylamino]butyl]-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N(CCCN1C(C2=CC=CC=C2NC1=O)=O)CCCCNCCCN1C(=O)C2=CC=CC=C2NC1=O TZKOJMOVKKJLNP-UHFFFAOYSA-N 0.000 claims description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
201000002212 progressive supranuclear palsy Diseases 0.000 claims description 4
230000010410 reperfusion Effects 0.000 claims description 4
IKDVRJMRBNZETD-UHFFFAOYSA-N 3-[3-[3-[3-(2,4-dioxo-1h-quinazolin-3-yl)propylamino]propylamino]propyl]-1h-quinazoline-2,4-dione Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCNCCCNCCCN1C(=O)C2=CC=CC=C2NC1=O IKDVRJMRBNZETD-UHFFFAOYSA-N 0.000 claims description 3
BBVXOMSJMHOIQX-UHFFFAOYSA-N 3-[3-[4-[3-(2,4-dioxo-1h-quinazolin-3-yl)propylamino]but-2-enylamino]propyl]-1h-quinazoline-2,4-dione Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCNCC=CCNCCCN1C(=O)C2=CC=CC=C2NC1=O BBVXOMSJMHOIQX-UHFFFAOYSA-N 0.000 claims description 3
201000006474 Brain Ischemia Diseases 0.000 claims description 3
206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
206010012289 Dementia Diseases 0.000 claims description 3
239000002168 alkylating agent Substances 0.000 claims description 3
229940100198 alkylating agent Drugs 0.000 claims description 3
125000006627 ethoxycarbonylamino group Chemical group 0.000 claims description 3
230000015654 memory Effects 0.000 claims description 3
MTNZMIRNZOTVOJ-UHFFFAOYSA-N n-[3-(2,4-dioxo-1h-quinazolin-3-yl)propyl]-n-[4-[3-(2,4-dioxo-1h-quinazolin-3-yl)propylamino]butyl]-2,2,2-trifluoroacetamide Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCN(C(=O)C(F)(F)F)CCCCNCCCN1C(=O)C2=CC=CC=C2NC1=O MTNZMIRNZOTVOJ-UHFFFAOYSA-N 0.000 claims description 3
IIQOGNFJNAQNSF-UHFFFAOYSA-N n-[3-(2,4-dioxo-1h-quinazolin-3-yl)propyl]-n-[4-[3-(2,4-dioxo-1h-quinazolin-3-yl)propylamino]butyl]-2-methoxyacetamide Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCN(C(=O)COC)CCCCNCCCN1C(=O)C2=CC=CC=C2NC1=O IIQOGNFJNAQNSF-UHFFFAOYSA-N 0.000 claims description 3
FHCLDCLNHMLSDU-UHFFFAOYSA-N n-[3-(2,4-dioxo-1h-quinazolin-3-yl)propyl]-n-[4-[3-(2,4-dioxo-1h-quinazolin-3-yl)propylamino]butyl]benzamide Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCNCCCCN(CCCN1C(C2=CC=CC=C2NC1=O)=O)C(=O)C1=CC=CC=C1 FHCLDCLNHMLSDU-UHFFFAOYSA-N 0.000 claims description 3
HYSJLMCJUFQPNR-UHFFFAOYSA-N n-[3-[4-[acetyl-[3-(2,4-dioxo-1h-quinazolin-3-yl)propyl]amino]butylamino]propyl]-4-hydroxybenzamide Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCN(C(=O)C)CCCCNCCCNC(=O)C1=CC=C(O)C=C1 HYSJLMCJUFQPNR-UHFFFAOYSA-N 0.000 claims description 3
UWVFLXFDUQHKBF-UHFFFAOYSA-N n-[3-[acetyl-[4-[3-(2,4-dioxo-1h-quinazolin-3-yl)propylamino]butyl]amino]propyl]-4-hydroxybenzamide Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCNCCCCN(C(=O)C)CCCNC(=O)C1=CC=C(O)C=C1 UWVFLXFDUQHKBF-UHFFFAOYSA-N 0.000 claims description 3
NJBJMOBTWOCPQR-UHFFFAOYSA-N n-[3-[acetyl-[4-[acetyl-[3-(2,4-dioxo-1h-quinazolin-3-yl)propyl]amino]butyl]amino]propyl]-4-hydroxybenzamide Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCN(C(C)=O)CCCCN(C(=O)C)CCCNC(=O)C1=CC=C(O)C=C1 NJBJMOBTWOCPQR-UHFFFAOYSA-N 0.000 claims description 3
208000020431 spinal cord injury Diseases 0.000 claims description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
JWAZCOLPZRXAMX-UHFFFAOYSA-N 1-hexyl-3-[3-[4-[3-(1-hexyl-2,4-dioxoquinazolin-3-yl)propylamino]butylamino]propyl]quinazoline-2,4-dione Chemical compound O=C1N(CCCCCC)C2=CC=CC=C2C(=O)N1CCCNCCCCNCCCN1C(=O)C2=CC=CC=C2N(CCCCCC)C1=O JWAZCOLPZRXAMX-UHFFFAOYSA-N 0.000 claims description 2
WVDPWYDGQCBXSV-UHFFFAOYSA-N 1-methyl-3-[3-[4-[3-(1-methyl-2,4-dioxoquinazolin-3-yl)propylamino]butylamino]propyl]quinazoline-2,4-dione Chemical compound O=C1N(C)C2=CC=CC=C2C(=O)N1CCCNCCCCNCCCN1C(=O)C2=CC=CC=C2N(C)C1=O WVDPWYDGQCBXSV-UHFFFAOYSA-N 0.000 claims description 2
KKARFJXBDDKSOI-UHFFFAOYSA-N 3-[3-[2-[3-(2,4-dioxo-1h-quinazolin-3-yl)propylamino]ethylamino]propyl]-1h-quinazoline-2,4-dione Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCNCCNCCCN1C(=O)C2=CC=CC=C2NC1=O KKARFJXBDDKSOI-UHFFFAOYSA-N 0.000 claims description 2
TXKISZGMPGCIPT-UHFFFAOYSA-N 3-[3-[4-[3-(1,3-dioxoisoindol-2-yl)propylamino]butylamino]propyl]-1h-quinazoline-2,4-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCCNCCCCNCCCN1C(=O)C2=CC=CC=C2NC1=O TXKISZGMPGCIPT-UHFFFAOYSA-N 0.000 claims description 2
QTZJVYXAEJQRRM-UHFFFAOYSA-N 3-[3-[4-[3-(2,4-dioxo-1h-quinazolin-3-yl)propyl-hexylamino]butylamino]propyl]-1h-quinazoline-2,4-dione Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCN(CCCCCC)CCCCNCCCN1C(=O)C2=CC=CC=C2NC1=O QTZJVYXAEJQRRM-UHFFFAOYSA-N 0.000 claims description 2
HAXIGGFPEXYILL-UHFFFAOYSA-N 3-[3-[4-[3-(2,5-dioxopyrrolidin-1-yl)propylamino]butylamino]propyl]-1h-quinazoline-2,4-dione Chemical compound O=C1CCC(=O)N1CCCNCCCCNCCCN1C(=O)C2=CC=CC=C2NC1=O HAXIGGFPEXYILL-UHFFFAOYSA-N 0.000 claims description 2
PYNOOSMDPQEGEE-UHFFFAOYSA-N 3-[3-[[3-[4-[benzyl-[3-(2,4-dioxo-1h-quinazolin-3-yl)propyl]amino]butyl]phenyl]methylamino]propyl]-1h-quinazoline-2,4-dione Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCNCC(C=1)=CC=CC=1CCCCN(CCCN1C(C2=CC=CC=C2NC1=O)=O)CC1=CC=CC=C1 PYNOOSMDPQEGEE-UHFFFAOYSA-N 0.000 claims description 2
206010002329 Aneurysm Diseases 0.000 claims description 2
206010003591 Ataxia Diseases 0.000 claims description 2
206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims description 2
208000025480 CHILD syndrome Diseases 0.000 claims description 2
206010058842 Cerebrovascular insufficiency Diseases 0.000 claims description 2
208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 claims description 2
208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 2
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 2
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
TWLLPUMZVVGILS-UHFFFAOYSA-N Ethyl 2-aminobenzoate Chemical compound CCOC(=O)C1=CC=CC=C1N TWLLPUMZVVGILS-UHFFFAOYSA-N 0.000 claims description 2
201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
206010018985 Haemorrhage intracranial Diseases 0.000 claims description 2
208000010496 Heart Arrest Diseases 0.000 claims description 2
206010019468 Hemiplegia Diseases 0.000 claims description 2
208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 2
206010021143 Hypoxia Diseases 0.000 claims description 2
208000028603 Interstitial lung disease specific to childhood Diseases 0.000 claims description 2
208000008574 Intracranial Hemorrhages Diseases 0.000 claims description 2
201000008450 Intracranial aneurysm Diseases 0.000 claims description 2
208000001089 Multiple system atrophy Diseases 0.000 claims description 2
208000028373 Neck injury Diseases 0.000 claims description 2
206010033892 Paraplegia Diseases 0.000 claims description 2
208000000609 Pick Disease of the Brain Diseases 0.000 claims description 2
208000032319 Primary lateral sclerosis Diseases 0.000 claims description 2
208000024777 Prion disease Diseases 0.000 claims description 2
208000009106 Shy-Drager Syndrome Diseases 0.000 claims description 2
208000032930 Spastic paraplegia Diseases 0.000 claims description 2
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 2
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 2
208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 2
208000032859 Synucleinopathies Diseases 0.000 claims description 2
208000022292 Tay-Sachs disease Diseases 0.000 claims description 2
208000032109 Transient ischaemic attack Diseases 0.000 claims description 2
206010046298 Upper motor neurone lesion Diseases 0.000 claims description 2
208000029028 brain injury Diseases 0.000 claims description 2
206010008129 cerebral palsy Diseases 0.000 claims description 2
230000001684 chronic effect Effects 0.000 claims description 2
230000001054 cortical effect Effects 0.000 claims description 2
230000003073 embolic effect Effects 0.000 claims description 2
230000001037 epileptic effect Effects 0.000 claims description 2
208000020658 intracerebral hemorrhage Diseases 0.000 claims description 2
208000037906 ischaemic injury Diseases 0.000 claims description 2
201000010901 lateral sclerosis Diseases 0.000 claims description 2
HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims description 2
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
208000005264 motor neuron disease Diseases 0.000 claims description 2
201000006417 multiple sclerosis Diseases 0.000 claims description 2
COSIVANBLIFRAF-UHFFFAOYSA-N n-[3-(2,4-dioxo-1h-quinazolin-3-yl)propyl]-n-[4-[3-(2,4-dioxo-1h-quinazolin-3-yl)propylamino]butyl]methanesulfonamide Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCN(S(=O)(=O)C)CCCCNCCCN1C(=O)C2=CC=CC=C2NC1=O COSIVANBLIFRAF-UHFFFAOYSA-N 0.000 claims description 2
208000020469 nerve plexus disease Diseases 0.000 claims description 2
230000001537 neural effect Effects 0.000 claims description 2
230000004770 neurodegeneration Effects 0.000 claims description 2
230000009251 neurologic dysfunction Effects 0.000 claims description 2
208000015015 neurological dysfunction Diseases 0.000 claims description 2
201000001119 neuropathy Diseases 0.000 claims description 2
230000007823 neuropathy Effects 0.000 claims description 2
239000003960 organic solvent Substances 0.000 claims description 2
230000009984 peri-natal effect Effects 0.000 claims description 2
208000033808 peripheral neuropathy Diseases 0.000 claims description 2
201000006380 plexopathy Diseases 0.000 claims description 2
230000004793 poor memory Effects 0.000 claims description 2
208000001282 primary progressive aphasia Diseases 0.000 claims description 2
208000032207 progressive 1 supranuclear palsy Diseases 0.000 claims description 2
201000008752 progressive muscular atrophy Diseases 0.000 claims description 2
230000001732 thrombotic effect Effects 0.000 claims description 2
201000010875 transient cerebral ischemia Diseases 0.000 claims description 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 10
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 6
150000002431 hydrogen Chemical class 0.000 claims 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
OABUHODTYXHKJB-UHFFFAOYSA-N 2-[3-(2,4-dioxo-1h-quinazolin-3-yl)propyl]-2-[4-[3-(2,4-dioxo-1h-quinazolin-3-yl)propylamino]butyl]heptanamide Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCC(C(N)=O)(CCCCC)CCCCNCCCN1C(=O)C2=CC=CC=C2NC1=O OABUHODTYXHKJB-UHFFFAOYSA-N 0.000 claims 1
KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 1
210000004558 lewy body Anatomy 0.000 claims 1
125000006239 protecting group Chemical group 0.000 claims 1
SDQJTWBNWQABLE-UHFFFAOYSA-N 1h-quinazoline-2,4-dione Chemical class C1=CC=C2C(=O)NC(=O)NC2=C1 SDQJTWBNWQABLE-UHFFFAOYSA-N 0.000 abstract description 12
238000011282 treatment Methods 0.000 abstract description 7
208000019736 Cranial nerve disease Diseases 0.000 abstract description 3
239000000126 substance Substances 0.000 abstract description 3
208000014826 cranial nerve neuropathy Diseases 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
239000007787 solid Substances 0.000 description 50
238000005160 1H NMR spectroscopy Methods 0.000 description 43
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
238000000034 method Methods 0.000 description 28
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 24
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 21
230000000694 effects Effects 0.000 description 21
210000004027 cell Anatomy 0.000 description 20
OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 20
230000002829 reductive effect Effects 0.000 description 19
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 18
230000002401 inhibitory effect Effects 0.000 description 16
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
238000010898 silica gel chromatography Methods 0.000 description 14
229940126214 compound 3 Drugs 0.000 description 13
231100000419 toxicity Toxicity 0.000 description 13
230000001988 toxicity Effects 0.000 description 13
210000004556 brain Anatomy 0.000 description 12
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 12
230000030833 cell death Effects 0.000 description 10
239000000243 solution Substances 0.000 description 10
125000001424 substituent group Chemical group 0.000 description 10
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 9
239000000523 sample Substances 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
102000019197 Superoxide Dismutase Human genes 0.000 description 8
108010012715 Superoxide dismutase Proteins 0.000 description 8
125000003545 alkoxy group Chemical group 0.000 description 8
210000004958 brain cell Anatomy 0.000 description 8
238000004440 column chromatography Methods 0.000 description 8
238000001914 filtration Methods 0.000 description 8
239000000741 silica gel Substances 0.000 description 8
229910002027 silica gel Inorganic materials 0.000 description 8
210000004204 blood vessel Anatomy 0.000 description 7
238000004821 distillation Methods 0.000 description 7
241000700159 Rattus Species 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
239000003814 drug Substances 0.000 description 6
239000001301 oxygen Substances 0.000 description 6
229910052760 oxygen Inorganic materials 0.000 description 6
230000008569 process Effects 0.000 description 6
239000003642 reactive oxygen metabolite Substances 0.000 description 6
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
210000002376 aorta thoracic Anatomy 0.000 description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
229940050390 benzoate Drugs 0.000 description 5
239000003937 drug carrier Substances 0.000 description 5
238000010438 heat treatment Methods 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
239000013642 negative control Substances 0.000 description 5
230000002040 relaxant effect Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 4
206010008089 Cerebral artery occlusion Diseases 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
102000003855 L-lactate dehydrogenase Human genes 0.000 description 4
108700023483 L-lactate dehydrogenases Proteins 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
230000001773 anti-convulsant effect Effects 0.000 description 4
230000006378 damage Effects 0.000 description 4
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
229940079593 drug Drugs 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 4
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
239000000725 suspension Substances 0.000 description 4
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 3
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 3
206010028851 Necrosis Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229910052783 alkali metal Inorganic materials 0.000 description 3
230000000320 anti-stroke effect Effects 0.000 description 3
229960003965 antiepileptics Drugs 0.000 description 3
239000002585 base Substances 0.000 description 3
210000005013 brain tissue Anatomy 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
210000000269 carotid artery external Anatomy 0.000 description 3
210000004004 carotid artery internal Anatomy 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
229930195712 glutamate Natural products 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000003456 ion exchange resin Substances 0.000 description 3
229920003303 ion-exchange polymer Polymers 0.000 description 3
239000010410 layer Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
201000007309 middle cerebral artery infarction Diseases 0.000 description 3
AMSUACYBQHKEGL-UHFFFAOYSA-N n-[4-[acetyl-[3-(2,4-dioxo-1h-quinazolin-3-yl)propyl]amino]butyl]-n-[3-(2,4-dioxo-1h-quinazolin-3-yl)propyl]acetamide Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCN(C(=O)C)CCCCN(C(C)=O)CCCN1C(=O)C2=CC=CC=C2NC1=O AMSUACYBQHKEGL-UHFFFAOYSA-N 0.000 description 3
230000017074 necrotic cell death Effects 0.000 description 3
239000002858 neurotransmitter agent Substances 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
230000036542 oxidative stress Effects 0.000 description 3
239000013641 positive control Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
150000003254 radicals Chemical class 0.000 description 3
238000010992 reflux Methods 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000000829 suppository Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
239000011701 zinc Substances 0.000 description 3
NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 3
229910000368 zinc sulfate Inorganic materials 0.000 description 3
MNDIARAMWBIKFW-UHFFFAOYSA-N 1-bromohexane Chemical compound CCCCCCBr MNDIARAMWBIKFW-UHFFFAOYSA-N 0.000 description 2
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
ZAXCZCOUDLENMH-UHFFFAOYSA-N 3,3,3-tetramine Chemical compound NCCCNCCCNCCCN ZAXCZCOUDLENMH-UHFFFAOYSA-N 0.000 description 2
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
206010010904 Convulsion Diseases 0.000 description 2
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
231100000002 MTT assay Toxicity 0.000 description 2
238000000134 MTT assay Methods 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
239000012359 Methanesulfonyl chloride Substances 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
238000011166 aliquoting Methods 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
239000001961 anticonvulsive agent Substances 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
210000001168 carotid artery common Anatomy 0.000 description 2
210000003710 cerebral cortex Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
229960001284 citicoline Drugs 0.000 description 2
238000006482 condensation reaction Methods 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
125000001183 hydrocarbyl group Chemical group 0.000 description 2
230000006698 induction Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
239000007758 minimum essential medium Substances 0.000 description 2
239000012046 mixed solvent Substances 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
WLDXKRHMTJRSGL-UHFFFAOYSA-N n-[3-(2,4-dioxo-1h-quinazolin-3-yl)propyl]-n-[4-[3-(2,4-dioxo-1h-quinazolin-3-yl)propyl-methylamino]butyl]acetamide Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCN(C)CCCCN(C(C)=O)CCCN1C(=O)C2=CC=CC=C2NC1=O WLDXKRHMTJRSGL-UHFFFAOYSA-N 0.000 description 2
OHCCHRKUEUIBCQ-UHFFFAOYSA-N n-[4-[benzyl-[3-(2,4-dioxo-1h-quinazolin-3-yl)propyl]amino]butyl]-n-[3-(2,4-dioxo-1h-quinazolin-3-yl)propyl]acetamide Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCN(C(=O)C)CCCCN(CCCN1C(C2=CC=CC=C2NC1=O)=O)CC1=CC=CC=C1 OHCCHRKUEUIBCQ-UHFFFAOYSA-N 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
230000001590 oxidative effect Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
229960001802 phenylephrine Drugs 0.000 description 2
239000006187 pill Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
238000010186 staining Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000008174 sterile solution Substances 0.000 description 2
125000003107 substituted aryl group Chemical group 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011686 zinc sulphate Substances 0.000 description 2
235000009529 zinc sulphate Nutrition 0.000 description 2
ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
QIMQRAOUTRFLRN-OWOJBTEDSA-N (e)-n,n'-bis(3-aminopropyl)but-2-ene-1,4-diamine Chemical compound NCCCNC\C=C\CNCCCN QIMQRAOUTRFLRN-OWOJBTEDSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
MGDYXRLSFHXKEL-UHFFFAOYSA-N 1-propylquinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)NC(=O)N(CCC)C2=C1 MGDYXRLSFHXKEL-UHFFFAOYSA-N 0.000 description 1
UWMHHZFHBCYGCV-UHFFFAOYSA-N 2,3,2-tetramine Chemical compound NCCNCCCNCCN UWMHHZFHBCYGCV-UHFFFAOYSA-N 0.000 description 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 1
125000005916 2-methylpentyl group Chemical group 0.000 description 1
RXFCIXRFAJRBSG-UHFFFAOYSA-N 3,2,3-tetramine Chemical compound NCCCNCCNCCCN RXFCIXRFAJRBSG-UHFFFAOYSA-N 0.000 description 1
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
OTIWXFLKEOCSMX-UHFFFAOYSA-N 3-[3-[benzyl-[4-[3-[[3-(2,4-dioxoquinazolin-1-yl)propylamino]methyl]phenyl]butyl]amino]propyl]-1h-quinazoline-2,4-dione Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCN(CCCCC=1C=C(CNCCCN2C(NC(=O)C3=CC=CC=C32)=O)C=CC=1)CC1=CC=CC=C1 OTIWXFLKEOCSMX-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
LJSMGWBQOFWAPJ-UHFFFAOYSA-N 4-methoxy-3-(naphthalen-1-ylmethyl)-4-oxobutanoic acid Chemical compound C1=CC=C2C(CC(CC(O)=O)C(=O)OC)=CC=CC2=C1 LJSMGWBQOFWAPJ-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
102000016938 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
QGISCXHVNHSGTK-UHFFFAOYSA-N Cl.Cl.O=C1N(C(CC1)=O)CCCNCCCCNCCCN1C(NC2=CC=CC=C2C1=O)=O Chemical compound Cl.Cl.O=C1N(C(CC1)=O)CCCNCCCCNCCCN1C(NC2=CC=CC=C2C1=O)=O QGISCXHVNHSGTK-UHFFFAOYSA-N 0.000 description 1
206010009346 Clonus Diseases 0.000 description 1
229940126657 Compound 17 Drugs 0.000 description 1
229940126639 Compound 33 Drugs 0.000 description 1
229940127007 Compound 39 Drugs 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241000426529 Eisenia andrei Species 0.000 description 1
241000243686 Eisenia fetida Species 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
239000004386 Erythritol Substances 0.000 description 1
UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
102000018899 Glutamate Receptors Human genes 0.000 description 1
108010027915 Glutamate Receptors Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
208000009829 Lewy Body Disease Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
235000009470 Theobroma cacao Nutrition 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
XLIJUKVKOIMPKW-BTVCFUMJSA-N [O].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O Chemical compound [O].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XLIJUKVKOIMPKW-BTVCFUMJSA-N 0.000 description 1
SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
229960000250 adipic acid Drugs 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical group 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000002082 anti-convulsion Effects 0.000 description 1
230000003064 anti-oxidating effect Effects 0.000 description 1
230000000573 anti-seizure effect Effects 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
229960004365 benzoic acid Drugs 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000003925 brain function Effects 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000004087 circulation Effects 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940125797 compound 12 Drugs 0.000 description 1
229940126543 compound 14 Drugs 0.000 description 1
229940125758 compound 15 Drugs 0.000 description 1
229940126142 compound 16 Drugs 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
229940125810 compound 20 Drugs 0.000 description 1
229940126086 compound 21 Drugs 0.000 description 1
229940126208 compound 22 Drugs 0.000 description 1
229940125833 compound 23 Drugs 0.000 description 1
229940125961 compound 24 Drugs 0.000 description 1
229940125846 compound 25 Drugs 0.000 description 1
229940125851 compound 27 Drugs 0.000 description 1
229940127204 compound 29 Drugs 0.000 description 1
229940125877 compound 31 Drugs 0.000 description 1
229940125878 compound 36 Drugs 0.000 description 1
229940125807 compound 37 Drugs 0.000 description 1
229940127573 compound 38 Drugs 0.000 description 1
229940126540 compound 41 Drugs 0.000 description 1
229940125936 compound 42 Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
210000003792 cranial nerve Anatomy 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
150000008050 dialkyl sulfates Chemical class 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000009509 drug development Methods 0.000 description 1
238000004043 dyeing Methods 0.000 description 1
UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
229940009714 erythritol Drugs 0.000 description 1
235000019414 erythritol Nutrition 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000013265 extended release Methods 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
229960002598 fumaric acid Drugs 0.000 description 1
239000003825 glutamate receptor antagonist Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229960004275 glycolic acid Drugs 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000007574 infarction Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229960000448 lactic acid Drugs 0.000 description 1
VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
230000003859 lipid peroxidation Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
229940098895 maleic acid Drugs 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
229940099690 malic acid Drugs 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
230000006993 memory improvement Effects 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
210000003657 middle cerebral artery Anatomy 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
HGNRTKOLXYAION-UHFFFAOYSA-N n-[4-(2,4-dioxo-1h-quinazolin-3-yl)butyl]-n-[3-(2,4-dioxo-1h-quinazolin-3-yl)propyl]acetamide Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCN(C(=O)C)CCCCN1C(=O)C2=CC=CC=C2NC1=O HGNRTKOLXYAION-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000005445 natural material Substances 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
230000007971 neurological deficit Effects 0.000 description 1
239000004090 neuroprotective agent Substances 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
239000002547 new drug Substances 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
229940074355 nitric acid Drugs 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
230000003546 nucleic acid damage Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
229960005010 orotic acid Drugs 0.000 description 1
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960004838 phosphoric acid Drugs 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
150000003141 primary amines Chemical group 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
229940095574 propionic acid Drugs 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
239000000376 reactant Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000004044 response Effects 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000003335 secondary amines Chemical group 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000035882 stress Effects 0.000 description 1
229940014800 succinic anhydride Drugs 0.000 description 1
229940032330 sulfuric acid Drugs 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229960001367 tartaric acid Drugs 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
230000009529 traumatic brain injury Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
210000001186 vagus nerve Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000037303 wrinkles Effects 0.000 description 1
239000008096 xylene Substances 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1
229960001763 zinc sulfate Drugs 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0906996-8A 2008-01-30 2009-01-08 Composto de quinazolino-2, 4-diona, processo para preparar um composto, e, composição farmacêutica BRPI0906996B1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
KR10-2008-0009390		2008-01-30
KR20080009390		2008-01-30
PCT/KR2009/000083 WO2009096667A2 (ko)	2008-01-30	2009-01-08	신규한 퀴나졸린-2,4-디온 유도체 및 이를 함유하는 뇌신경질환 예방 및 치료용 의약 조성물

Publications (2)

Publication Number	Publication Date
BRPI0906996A2 BRPI0906996A2 (pt)	2015-07-07
BRPI0906996B1 true BRPI0906996B1 (pt)	2021-06-22

Family

ID=40913386

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0906996-8A BRPI0906996B1 (pt)	2008-01-30	2009-01-08	Composto de quinazolino-2, 4-diona, processo para preparar um composto, e, composição farmacêutica

Country Status (20)

Country	Link
US (2)	US8404696B2 (ja)
EP (1)	EP2239257B1 (ja)
JP (1)	JP5291124B2 (ja)
KR (1)	KR101075435B1 (ja)
CN (1)	CN101925585B (ja)
AR (1)	AR074372A1 (ja)
AU (1)	AU2009209811B2 (ja)
BR (1)	BRPI0906996B1 (ja)
CA (1)	CA2712819C (ja)
CO (1)	CO6290762A2 (ja)
DK (1)	DK2239257T3 (ja)
EA (1)	EA018142B1 (ja)
ES (1)	ES2387539T3 (ja)
IL (1)	IL206738A (ja)
MY (1)	MY153733A (ja)
NZ (1)	NZ586552A (ja)
PL (1)	PL2239257T3 (ja)
PT (1)	PT2239257E (ja)
WO (1)	WO2009096667A2 (ja)
ZA (1)	ZA201004546B (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2239257E (pt)	2008-01-30	2012-09-12	Shin Poong Pharmaceutical Co Ltd	Novo derivado de quinazolina-2,4-diona e composições médicas para a profilaxia e tratamento da doença dos nervos cranianos contendo o dito derivado
US8337902B2 (en) *	2008-09-25	2012-12-25	Wisconsin Alumni Research Foundation	Degradation of prion protein and reduced prion infectivity by earthworm homogenates
CN103517890B (zh) *	2011-05-02	2016-08-17	弗纳技术股份有限公司	乙苯生产方法
KR102061183B1 (ko) *	2014-01-20	2019-12-31	웰 스톤 유겐가이샤	카테콜라민 생산 촉진제, 카테콜라민의 결핍에 기인하는 질환의 치료약·예방약 및 치료용·예방용 식품 조성물
JP7203495B2 (ja) *	2015-06-15	2023-01-13	コーニンクレッカフィリップスエヌヴェ	改善されたノズル設計を具備する口腔清掃装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9400680D0 (en) *	1994-01-14	1994-03-09	Sandoz Ltd	Improvements in or relating to organic compounds
CN1103772C (zh)	1996-05-15	2003-03-26	辉瑞大药厂	新的2,3－二取代－4(3h)－喹唑啉酮类化合物
US6060479A (en)	1997-06-09	2000-05-09	Pfizer Inc	Quinazoline-4-one AMPA antagonists
ATE360423T1 (de) *	1999-11-01	2007-05-15	Daiichi Asubio Pharma Co Ltd	Verwendung von chymase hemmern gegen vaskuläre lipidablagerung
SK10572002A3 (sk) *	2000-01-24	2003-10-07	Warner-Lambert Company	3-Aminochinazolín-2,4-diónové antibakteriálne činidlá
JP2004527535A (ja) *	2001-04-11	2004-09-09	クイーンズ　ユニバーシティ　アット　キングストン	抗発作発生剤および／または抗癲癇誘発剤としてのピリミジン化合物
DE10201240A1 (de) *	2002-01-15	2003-07-24	Bayer Ag	Substituierte Alkyluracile und ihre Verwendung
GB0416730D0 (en) *	2004-07-27	2004-09-01	Novartis Ag	Organic compounds
TWI396543B (zh) *	2005-05-12	2013-05-21	Sankyo Co	取代丙烯醯胺衍生物及含有它之醫藥組成物
US8586619B2 (en)	2007-03-12	2013-11-19	Vm Therapeutics Llc	Agents of calcium ion channel modulators
PT2239257E (pt)	2008-01-30	2012-09-12	Shin Poong Pharmaceutical Co Ltd	Novo derivado de quinazolina-2,4-diona e composições médicas para a profilaxia e tratamento da doença dos nervos cranianos contendo o dito derivado

2009
- 2009-01-08 PT PT09705187T patent/PT2239257E/pt unknown
- 2009-01-08 BR BRPI0906996-8A patent/BRPI0906996B1/pt active IP Right Grant
- 2009-01-08 AU AU2009209811A patent/AU2009209811B2/en active Active
- 2009-01-08 EA EA201070898A patent/EA018142B1/ru not_active IP Right Cessation
- 2009-01-08 US US12/863,332 patent/US8404696B2/en active Active
- 2009-01-08 KR KR1020090001655A patent/KR101075435B1/ko active Active
- 2009-01-08 EP EP09705187A patent/EP2239257B1/en active Active
- 2009-01-08 JP JP2010544881A patent/JP5291124B2/ja active Active
- 2009-01-08 PL PL09705187T patent/PL2239257T3/pl unknown
- 2009-01-08 CN CN2009801032365A patent/CN101925585B/zh active Active
- 2009-01-08 DK DK09705187.4T patent/DK2239257T3/da active
- 2009-01-08 NZ NZ586552A patent/NZ586552A/en unknown
- 2009-01-08 ES ES09705187T patent/ES2387539T3/es active Active
- 2009-01-08 WO PCT/KR2009/000083 patent/WO2009096667A2/ko not_active Ceased
- 2009-01-08 CA CA2712819A patent/CA2712819C/en active Active
- 2009-01-08 MY MYPI2010003123A patent/MY153733A/en unknown
- 2009-11-19 AR ARP090104459A patent/AR074372A1/es active IP Right Grant
2010
- 2010-06-28 ZA ZA2010/04546A patent/ZA201004546B/en unknown
- 2010-06-30 IL IL206738A patent/IL206738A/en active IP Right Grant
- 2010-07-29 CO CO10092621A patent/CO6290762A2/es active IP Right Grant
2012
- 2012-12-11 US US13/710,543 patent/US9290480B2/en active Active

Also Published As

Publication number	Publication date
EA018142B1 (ru)	2013-05-30
CA2712819C (en)	2013-07-23
EP2239257A2 (en)	2010-10-13
IL206738A (en)	2014-05-28
KR101075435B1 (ko)	2011-10-24
CO6290762A2 (es)	2011-06-20
WO2009096667A4 (ko)	2009-12-03
CN101925585A (zh)	2010-12-22
CA2712819A1 (en)	2009-08-06
IL206738A0 (en)	2010-12-30
HK1149263A1 (en)	2011-09-30
US8404696B2 (en)	2013-03-26
JP2011510978A (ja)	2011-04-07
NZ586552A (en)	2012-06-29
WO2009096667A2 (ko)	2009-08-06
ES2387539T3 (es)	2012-09-25
KR20090083848A (ko)	2009-08-04
AU2009209811B2 (en)	2011-07-21
US9290480B2 (en)	2016-03-22
PL2239257T3 (pl)	2012-10-31
WO2009096667A3 (ko)	2009-10-08
BRPI0906996A2 (pt)	2015-07-07
ZA201004546B (en)	2011-04-28
DK2239257T3 (da)	2012-08-13
US20130102622A1 (en)	2013-04-25
AU2009209811A1 (en)	2009-08-06
EP2239257B1 (en)	2012-06-06
EP2239257A4 (en)	2011-06-22
MY153733A (en)	2015-03-13
PT2239257E (pt)	2012-09-12
US20100311769A1 (en)	2010-12-09
CN101925585B (zh)	2013-04-17
JP5291124B2 (ja)	2013-09-18
AR074372A1 (es)	2011-01-12
EA201070898A1 (ru)	2011-02-28

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2020-06-02	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2020-11-17	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-12-08	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-12-08	B15K	Others concerning applications: alteration of classification	Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 239/96 Ipc: C07D 239/96 (2006.01), A61K 31/517 (2006.01), A61P
2021-03-09	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-05-25	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-06-22	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/01/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

Publication	Publication Date	Title
ES2368691T3 (es)	2011-11-21	Derivados de benzotiazepina y su utilización como moduladores de los receptores ampa y nmda.
KR101186386B1 (ko)	2012-09-26	Ｓ１ｐ 수용체 결합능을 갖는 화합물 및 그 의약 용도
RU2045522C1 (ru)	1995-10-10	Диаминовые соединения или их кислотно-аддитивные соли
EP1760071A1 (en)	2007-03-07	Compound having s1p receptor binding potency and use thereof
JP2017538676A (ja)	2017-12-28	ミトコンドリア透過性遷移孔（ｍｔＰＴＰ）の小分子阻害剤
CN102036956A (zh)	2011-04-27	取代的吡咯烷和哌啶化合物、它们的衍生物、以及用于治疗疼痛的方法
BRPI0906996B1 (pt)	2021-06-22	Composto de quinazolino-2, 4-diona, processo para preparar um composto, e, composição farmacêutica
JPS62267250A (ja)	1987-11-19	抗不整脈剤
BRPI0708816A2 (pt)	2011-06-14	2-amino-4-fenildihidroquinolinas substituÍdas, processo para preparaÇço das mesmas, uso das mesmas como medicamentos, e medicamentos as compreendendo
CA3017048A1 (en)	2017-09-28	Benzenesulfonyl-asymmetric ureas and medical uses thereof
EP4211114A1 (en)	2023-07-19	Small molecule inhibitors of enpp1
TWI519524B (zh)	2016-02-01	新穎之喹唑啉－２，４－二酮衍生物及用於預防或治療神經性腦部疾病之醫藥組成物
HK1149263B (en)	2013-12-13	Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
HK1167404B (en)	2015-08-14	Benzothiadiazepine derivatives used as ampa and nmda receptor modulators